Catalent: Broad Drug Delivery Technologies

| November 11, 2011

article image
Catalent's range of drug delivery technologies helps companies because it constitutes a toolkit. Just like any other toolkit that you would use that allows you to do the most difficult jobs that you have in front of you, a broad drug delivery toolkit that ranges from controlled release and modified release technologies, to softgel, to hot-melt extrusion, allows us to be able to tackle the toughest problems that our customers have with poorly soluble molecules.

Spotlight

Fidia Farmaceutici SpA

Privately held, fully integrated Italian pharmaceutical company, with R&D, manufacturing, marketing, and sales capabilities. Fidia Farmaceutici S.p.A founded in Bologna (Italy) in 1946 and relocated to Abano Terme (Italy) in 1959, is part of the P & R Group since 1999, ranked among the top ten national chemical groups. The Group counts more than 1.800 employees, distributed between the chemical and pharmaceutical market segments.

OTHER ARTICLES

WANT LESS “LIABILITY” AND MORE “RELIABILITY” FROM YOUR CLINICAL MOBILITY SOLUTION?

Article | March 2, 2020

I recently discussed the different ways that consumer-grade smartphones can compromise patients’ health, safety and overall care. However, some clinicians and healthcare administrators have indicated in recent months that they need help selecting the right enterprise-grade mobility solutions for their unique operating models and workflows. There are many different hardware and software options, and a single rugged device can come in multiple configurations. So, how do you know if you’re picking the right communication tools for your clinicians? The key is to first set performance expectations for the total mobility solution rather than the device alone.

Read More

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | March 2, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | March 2, 2020

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

Merck’s Patient-Centric Clinical Trial Recruiting

Article | March 2, 2020

Everyone in pharma knows that product success depends on the results of clinical trials — but we don’t usually hear from the people who are involved in running them. Recently, four Clinical Research Managers (CRM) from Merck (known as MSD outside the United States and Canada) discussed how Merck is overcoming the barriers to clinical trial recruitment by adopting a patient-centric process — a model that affects their trials top to bottom, from design through implementation. Each of the panel members manages clinical trials, serving as the main point of interaction with the Clinical Research Associates (CRAs) on research requirements, goals, and resources, including recruiting and retention.

Read More

Spotlight

Fidia Farmaceutici SpA

Privately held, fully integrated Italian pharmaceutical company, with R&D, manufacturing, marketing, and sales capabilities. Fidia Farmaceutici S.p.A founded in Bologna (Italy) in 1946 and relocated to Abano Terme (Italy) in 1959, is part of the P & R Group since 1999, ranked among the top ten national chemical groups. The Group counts more than 1.800 employees, distributed between the chemical and pharmaceutical market segments.

Events